Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference
November 29 2020 - 8:19PM
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), is pleased
to announce that Dr. Henry Ji, Chairman and CEO, will be
participating in the Piper Sandler 32nd Annual Virtual Healthcare
Conference.
A pre-recorded presentation is made available to participants
and the public, in addition to 1 on 1 virtual meetings with
selected investors taking place between 11/30/20 and 12/03/20.
Dr. Ji Pre-Recorded Investor Presentation can be accessed at the
following Link:
https://pipersandler.zoom.us/rec/play/7p6ebIhHbRkmmBaXffNQeGXSsRkhriEV56NBSFVTRQ9IBnxL6C4uvSfjlZXAayBAeewv7zWyCwLtr2XR.qMOgbDXGYEyaZYt2
(Note: Link expires 90 days after date of recording).
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc. under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Certain
statements contained in this presentation or in other documents of
Sorrento Therapeutics, Inc. (the “Company” or “Sorrento”) and of
any of its affiliates, along with certain statements that may be
made by management of the Company orally in presenting this
material, are or may be considered “forward-looking statements” as
defined in the Private Securities Litigation Reform Act of 1995.
These statements can be identified by the fact that they do not
relate strictly to historic or current facts. They use words such
as "estimate," "expect," "intend," "believe," "plan," "anticipate,"
“potential,” “projected” and other words and terms of similar
meaning in connection with any discussion of future operating or
financial performance or condition. Sorrento cautions that these
statements are based upon the current beliefs and expectations of
the Company's management and are subject to significant risks and
uncertainties. Statements regarding future action, future
performance and/or future results including, without limitation,
those relating to the timing for completion, and results of,
scheduled or additional clinical trials and the FDA’s or other
regulatory review and/or approval and commercial launch and sales
results (if any) of the Company’s formulations and products and
regulatory filings related to the same, and receipt by the Company
of milestone and royalty payments may differ from those set forth
in the forward-looking statements. Peak sales and market size
estimates have been determined on the basis of market research and
comparable product analysis, but no assurances can be given that
such sales levels will be achieved, if at all, or that such market
size estimates will prove accurate.
The Company assumes no obligation to update forward-looking
statements as circumstances change. Investors are advised to
consult further disclosures that the Company makes or has made on
related subjects in the Company’s most recent periodic reports
filed with the Securities and Exchange Commission, including
Sorrento’s Annual Report on Form 10-K for the year ended December
31, 2019 and subsequent Quarterly Reports on Form 10-Q filed with
the Securities and Exchange Commission, including the risk factors
set forth in those filings.
In presenting this material or responding to inquiries in
connection with a presentation, management may refer to results,
projections or performance measures that are not prepared in
accordance with U.S. Generally Accepted Accounting Principles
(“GAAP”) as reported in the Company’s SEC filings. These results,
projections or performance measures are non-GAAP measures and are
not intended to replace or substitute for results measured under
GAAP and are supplemental to GAAP reported results.
Because actual results are affected by these and other potential
risks, contingencies and uncertainties, the Company cautions
investors that actual results may differ materially from those
expressed or implied in any forward-looking statement. It is not
possible to predict or identify all such risks, contingencies and
uncertainties. The Company identifies some of these factors in its
SEC filings on Forms 10-K, 10-Q and 8-K, including Sorrento’s
Annual Report on Form 10-K for the year ended December 31, 2019 and
subsequent Quarterly Reports on Form 10-Q filed with the Securities
and Exchange Commission, including the risk factors set forth in
those filings. Investors are advised to consult the Company’s
filings for a more complete listing of risk factors, contingencies
and uncertainties affecting the Company and its business and
financial performance.
Media and Investor Relations
Contact: Alexis Nahama, DVM (SVP Corporate Development)
Telephone: 1.858.203.4120
Email: mediarelations@sorrentotherapeutics.com
ZTlido® and G-MAB™ are trademarks owned by Scilex
Pharmaceuticals Inc. and Sorrento, respectively.
Seprehvir®, is a registered trademark of Virttu Biologics
Limited, a wholly owned subsidiary of TNK Therapeutics, Inc. and
part of the group of companies owned by Sorrento Therapeutics,
Inc.
All other trademarks are the property of their respective
owners.© 2020 Sorrento Therapeutics, Inc. All Rights
Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Sep 2023 to Sep 2024